Effects of Denosumab on Bone Mineral Density and Bone Turnover in Postmenopausal Women

McWhorter School of Pharmacy, Samford University, Birmingham, Alabama 35229, USA.
Pharmacotherapy (Impact Factor: 2.66). 05/2011; 31(5):510-23. DOI: 10.1592/phco.31.5.510
Source: PubMed


Osteoporosis is a degenerative bone disease affecting approximately 10 million American adults. Several options are available to prevent development of the disease or slow and even stop its progression. Nonpharmacologic measures include adequate intake of calcium and vitamin D, exercise, fall prevention, and avoidance of tobacco and excessive alcohol intake. Current drug therapy includes bisphosphonates, calcitonin, estrogen or hormone therapy, selective estrogen receptor modulators, and teriparatide. Denosumab, a receptor activator of nuclear factor-K B ligand (RANKL) inhibitor, was recently approved by the United States Food and Drug Administration for treatment of postmenopausal osteoporosis. Patients treated with denosumab experienced significant gains in bone mineral density, rapid reductions in markers of bone turnover, and a reduced risk for new vertebral fracture. Compared with placebo, patients receiving denosumab 60 mg subcutaneously once every 6 months experienced gains in bone mineral density of 6.5-11% when treated for 24-48 months. One trial demonstrated the superiority of denosumab compared with alendronate, but the differences were small. The most common adverse reactions to denosumab include back pain, pain in extremities, musculoskeletal pain, and cystitis. Serious, but rare, adverse reactions include the development of serious infections, dermatologic changes, and hypocalcemia. The recommended dosing of denosumab is 60 mg every 6 months as a subcutaneous injection in the upper arm, upper thigh, or abdomen. Although beneficial effects on bone mineral density and fracture rate have been established in clinical trials, the risks associated with denosumab must be evaluated before therapy initiation. Of concern is the risk of infection, and denosumab should likely be avoided in patients taking immunosuppressive therapy or at high risk for infection. Therefore, bisphosphonates will likely remain as first-line therapy. Denosumab should be considered in patients unable to tolerate or who have adherence issues or contraindications to other therapies.

18 Reads
  • Source
    • "cytokines and increases osteoclast activity provoking bone resorption , which leads to a high bone turnover and bone loss as well (Fraser et al., 2011; Kearns et al., 2008; Wensel et al., 2011). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Postmenopausal osteoporosis is one of the most common disorders in women after menopause, which is linked to an estrogen deficiency and characterized by an excessive loss of trabecular bone. Rubus coreanus and Astragalus membranaceus have been used for their various pharmacological properties in Asia as a traditional medicine. The present study evaluated the anti-osteoporotic effects of the optimal combination of R. coreanus and A. membranaceus in 7:3 mixture (RAM) in ovariectomized (OVX) mice by investigating bone biomechanical properties and the serum levels of TNF-α, osteocalcin, RANKL, OPG, and RANK-RANKL signal-related osteoclast differentiation markers. A total of 36 mature female outbred ICR (Institute of cancer research) strain mice (7 weeks) were divided into 6 groups with 7 mice in each group as follows: (1) Sham-operated control mice (Sham) received daily oral phosphate-buffered-saline (PBS) of equal volumes through gavage. (2) OVX mice received a daily oral gavage of PBS (OVX). (3) OVX mice treated daily with 50mg/kg b.w./day of RAM (4) with 100mg/kg b.w./day of RAM or (5) with 200mg/kg b.w./day of RAM via oral gavage. (6) OVX mice received i.p. injections of 17β-estradiol (E2) (0.1mg/kg b.w./day) three times per week for 12wk. Micro-CT images showed that oral administration of RAM to OVX mice prevented tibial bone loss, preserved trabecular bone microarchitecture, and improved bone biomechanical properties. RAM administration also showed recovery effects on the levels of TNF-α, OPG and RANKL concentration in OVX-states. Additionally, we found that the mechanism by which RAM elicited anti-osteoporotic effects was by down-regulating the expression of TRAF6 and NFATc1 in RANKL-RANK pathway, a route of osteoclast differentiation, followed by reducing the production of osteoclast differentiation factors, calcitonin receptors and cathepsin K. Our research strongly suggests that RAM can be clinically used in the prevention and treatment of postmenopausal osteoporosis.
    Journal of ethnopharmacology 12/2013; 151(2). DOI:10.1016/j.jep.2013.12.008 · 3.00 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Bone metabolism can be assessed by measuring bone turnover markers in serum or urine. Bone turnover markers are substances released from bone during bone turnover. They can be skeletal tissue proteins, collagen fragments, peptides, or enzymes released from bone cells. Bone turnover markers are extensively used in research applications but also as tools for the management of skeletal disorders in clinical practice. Osteoporosis-related applications may include assessment of response to, or deciding on osteoporosis therapy; identification of individuals with increased bone loss, and prediction of risk for fragility fractures. Advancements in the development of assays to measure bone markers has made the measurements available also for clinical practice. The possibility to use them in various aspects of clinical practice has been tested in the recent years and given promising results. Monitoring the efficacy of bone-active drugs is currently the most promising application for bone turnover markers. Some markers, particularly resorption markers may also be useful in identifying individuals who are at high risk for bone loss and future fracture. In this article we discuss some potential applications of currently available bone turnover markers in postmenopausal osteoporosis.
    Clinical Reviews in Bone and Mineral Metabolism 03/2009; 8(1):1-14. DOI:10.1007/s12018-009-9042-x
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Osteoporosis is a worldwide health problem characterised by a reduction in bone mass and deterioration of bone-tissue microarchitecture, which can lead to compromised bone strength and an increased risk of fracture. While the currently available antiosteoporotic treatments have shown satisfactory antifracture efficacy, they may be associated with some safety concerns and poor patient compliance. The physiology of bone loss in osteoporosis and the mechanism of action of antiosteoporosis treatments only began to be elucidated within the last decade. The receptor activator for nuclear factor κB ligand (RANKL) is considered necessary for osteoclast genesis and function and, hence, bone resorption. A RANKL-targeted monoclonal antibody, denosumab, has been evaluated as a novel antiresorptive treatment. It has been shown to significantly increase bone mineral density at the hip, spine and distal third of the radius, and also to significantly reduce the risk of fractures, in post-menopausal osteoporotic women who have an increased risk of fracture. After extensive clinical trials, denosumab was filed with the European Medicines Agency (EMEA) for the treatment of post-menopausal osteoporosis and for bone loss in patients undergoing hormone ablation therapy for breast or prostate cancer.
Show more